All In Biotech

Drug Trial Radar · NCT07226349

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Dec 11, 2025

Primary completion

Nov 1, 2028

Study completion Nov 1, 2028

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • BG-75098Drug

    Administered orally.

  • BGB-43395Drug

    Administered orally.

  • FulvestrantDrug

    Administered by intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Number of Participants with Adverse Events (AEs)Time frame: From first dose to 30 days after last dose, up to approximately 12 months
  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-75098Time frame: Up to approximately 2 years
  3. Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-75098 as Monotherapy and in Combination with BGB-43395 and FulvestrantTime frame: Up to approximately 2 years
  4. Phase 1b: Objective Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to approximately 2 years

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham Hospital

    Birmingham, Alabama · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Sidney Kimmel Comprehensive Cancer At Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Next Oncology Houston

    Houston, Texas · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia · Recruiting

  • Genesiscare St Leonards

    St Leonards, New South Wales, Australia · Recruiting

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, Australia · Recruiting

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • One Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Province Hospital Longjiang Branch

    Nanjing, Jiangsu, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Weifang Peoples Hospital

    Weifang, Shandong, China · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.